Camurus appoints Alberto Pedroncelli as Chief Medical Officer
Lund, Sweden — 4 April 2023 — Camurus AB (NASDAQ STO: CAMX) today announced the appointment of Alberto M. Pedroncelli, MD, PhD, as Chief Medical Officer and member of the company’s executive management team from 1 June 2023.
Dr Perdoncelli is a leading global expert in clinical development and medical affairs within the field of endocrinology and oncology. He joins Camurus from a position as head of clinical development & medical affairs, global endocrinology at Recordati. Prior to this, he spent 12 years in different senior leadership positions at Novartis with responsibility for global clinical programs in rare diseases, including the successful US and European regulatory submissions of osilodrostat (Isturisa®) for treatment of Cushing’s syndrome. Alberto began his tenure at Novartis as global brand medical director for Sandostatin® and Signifor® within the Oncology Business Unit.
Before joining Novartis, he served as a clinician and research fellow at the Department of Endocrinology, University Hospital Bergamo, Italy, with focus on pituitary tumors and acromegaly.
“We are delighted to have Alberto joining Camurus as our new Chief Medical Officer ahead of Phase 3 results and planned regulatory submissions for CAM2029”, says Fredrik Tiberg, President and CEO of Camurus. “Alberto’s strong commitment to patient care, leading position in the endocrine and neuroendocrine cancer communities and track record from successful clinical development and market access processes for global pharmaceutical brands in rare disease areas makes him a great addition to our growing team at Camurus”, he continues.
“I have followed Camurus for many years and I am impressed by the company's development, unique technology platform and promising portfolio of drug candidates for treatment of rare diseases, not least CAM2029," says Alberto M. Pedroncelli. "The product has several potential benefits for patients and the possibility of becoming a new standard treatment for acromegaly and neuroendocrine tumors. I look forward to working together with my talented colleagues at Camurus to increase the availability of effective treatments for patients with severe and often chronic medical conditions," he continues.
Dr Pedroncelli succeeds Peter Hjelmström, who after eight productive years as Chief Medical Officer has left Camurus for other engagements.
For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92
Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
Camurus is a Swedish, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of cancer, endocrine diseases, pain and addiction, which are developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit camurus.com.
The information was submitted for publication at 02:00 pm CET on 4 April 2023.